A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery.
about
Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesAdministration of low molecular weight and unfractionated heparin during percutaneous coronary interventionMeasuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewMeta-analysis and suggested guidelines for prevention of venous thromboembolism (VTE) in foot and ankle surgeryClinical application of enoxaparin.Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.Low molecular weight heparins: an emerging new class of glycosaminoglycan antithrombotics.Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement.An evaluation of the biological response to Fraxiparine, (a low molecular weight heparin) in the healthy individual.Contemporary use of and future roles for heparin in antithrombotic therapy.Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange.Benefits of novel oral anticoagulant agents for thromboprophylaxis after total hip or knee arthroplasty.Radiology interventions in patients receiving low molecular weight heparin: timing is critical.Low molecular weight heparin in prevention of perioperative thrombosis.Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacementSelective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery.Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism.Anticoagulant drugs in the elderly: valuable in selected patientsThromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].Incidence of venous thromboembolism using 64 channel multidetector row computed tomography-indirect venography and anti-coagulation therapy after total knee arthroplasty in Korea.Low dose compared to variable dose Warfarin and to Fondaparinux as prophylaxis for thromboembolism after elective hip or knee replacement surgery; a randomized, prospective study.The principles and practice of anticoagulant therapy.The British Society for Haematology Guidelines on the use and monitoring of heparin 1992: second revision. BCSH Haemostasis and Thrombosis Task ForceAntithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations.Enoxaparin: a pharmacologic and clinical review.Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulantsPrevention of venous thromboembolism in general surgical patients. Results of meta-analysis.Changes in mortality patterns following total hip or knee arthroplasty over the past two decades: a nationwide cohort study.Deep venous thrombosis following different isolated lower extremity fractures: what is known about prevalences, locations, risk factors and prophylaxis?Venous thromboembolism in neurosurgery and neurology patients: a review.Enoxaparin: the low-molecular-weight heparin for prevention of postoperative thromboembolic complications.Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism.Biomarkers of Coagulation and Fibrinolysis during Cemented Total Hip Arthroplasty with Pre- versus Postoperative Start of Thromboprophylaxis.Results of adjusted-dose heparin for thromboembolism prophylaxis in knee replacement compared to those found for its use in hip fracture surgery and elective hip replacement.Major orthopaedic surgery on the leg and thromboembolism.Deep vein thrombosis after total hip arthroplasty and total knee arthroplasty in patients with previous ischemic stroke.Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study.Retrospective administrative database study of the time period of venous thromboembolism risk during and following hospitalization for major orthopedic or abdominal surgery in real-world US patients.
P2860
Q24632872-D2E12335-CF86-4EAA-BD83-126080D92C6EQ26748752-1110EA17-77FA-4349-952E-5ACCD4B3CE9CQ26992262-0C3BB93F-A4B3-4A09-9154-A02A8B845000Q28072799-51EAF424-FA48-43EB-A4F3-6DCC3208E306Q33360866-0D9F5FEF-7609-4A79-944C-6B59853CD7B0Q33360869-ABDFE701-067F-46E0-B5A3-2CA6876AEBC2Q33370169-D05D2AA6-1BD6-4856-BA57-71DCB5C12D0FQ33370626-92CFD68A-952D-4E40-B743-E41A6A20546FQ33393874-4362E0F8-E358-4EE9-A6F3-34E3E85F14EAQ33395878-545F27F5-70B3-4F82-B9D8-A71F0BE5BD6CQ33495687-8B41E6E6-6631-4543-A018-362D0ACD5010Q33685447-2B15A4B3-BCFA-4601-9AF2-119ACBD3EC95Q33714792-FE2118BC-DECE-4355-B9A5-805E0902360DQ34352619-B78A4785-87B4-4A26-B4FA-77FDC2A661CDQ34534567-9EF684D8-2BCD-41F0-841D-CB22B36CE763Q34708293-B59BBAAB-2C2E-480F-ADCC-0EDFB5FBA54CQ35160253-A32C981F-4833-4225-8C58-7AC2F92FB6FFQ35567223-75C29860-A5C7-452C-A155-28E459E1B9D9Q35704478-1567BA14-E27F-45F8-9CC8-56334AF5ABAAQ35851245-581F7F1F-6FFA-4782-8643-E25C86BA1231Q35926975-1B47E29F-BB8D-488B-A6E0-D25183D2F831Q36131612-269B94A9-A21C-4D45-94C4-A88D945A603AQ36414660-39DE1DAA-A56E-4095-AFF9-627FE2BE9310Q37232098-1A3363C1-CB36-49AA-AEC4-AC8B5A669761Q37472172-54EA4DC1-DC21-4F70-87E2-BADD26403D7EQ37862264-216E8585-47C2-4C85-825A-22AE6316A3ECQ37956637-10831611-E2CD-4DF0-899A-DE83D9C1CBD2Q38190938-24AE0CC8-2651-4097-A8B9-41C5BBE2F8CCQ38422371-3BA0F86C-7DB4-4608-B487-F61D99D6CCB4Q40055961-20B8F85F-0DD5-43EB-85B4-0340B992B858Q40749842-E37C688E-785B-4886-9975-17C184DE9A52Q40785836-C4E1FAB0-6D3F-4FD2-B3AF-12A51AA2E3F1Q42718620-461F68CB-0E34-4803-8C35-14DCD64E857AQ42767676-0E385714-CFE6-4F1E-850A-359BC90C821EQ42859772-713CA20D-15E8-4AC5-A13A-CF0091AC6409Q43163101-BD25093E-D4CE-40A6-862E-C00079FE1A7EQ43484858-7AFD4302-E971-43DA-9018-DD7EA2B345C7Q43611676-2A0191EC-865B-4586-92AA-A17E38E1FD04Q44051982-031C925D-1B4B-4857-A889-FBF020EE9B6EQ44132240-93A2A86E-F4BE-4AAC-8B02-8BF40095E4D6
P2860
A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery.
description
1986 nî lūn-bûn
@nan
1986 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
A randomized controlled trial ...... dergoing elective hip surgery.
@ast
A randomized controlled trial ...... dergoing elective hip surgery.
@en
A randomized controlled trial of a low-molecular-weight heparin
@nl
type
label
A randomized controlled trial ...... dergoing elective hip surgery.
@ast
A randomized controlled trial ...... dergoing elective hip surgery.
@en
A randomized controlled trial of a low-molecular-weight heparin
@nl
prefLabel
A randomized controlled trial ...... dergoing elective hip surgery.
@ast
A randomized controlled trial ...... dergoing elective hip surgery.
@en
A randomized controlled trial of a low-molecular-weight heparin
@nl
P2093
P1476
A randomized controlled trial ...... dergoing elective hip surgery.
@en
P2093
P304
P356
10.1056/NEJM198610093151503
P407
P577
1986-10-01T00:00:00Z